Latest Breaking News On - Glenn chertow - Page 1 : comparemela.com

How Can Cardiovascular Risk Be Reduced in Kidney Dialysis?

The experimental IL-6 inhibitor clazakizumab improves key inflammation markers in one study, whereas another shows lower risks with home hemodialysis vs peritoneal dialysis.

United statesStanford universityUniversity of cincinnatiPeter stenvinkelGlenn chertowSilvi shahDivision of nephrologyDivision of renal medicine at karolinska institutetStanford university school of medicineEuropean renal association congressEuropean renal associationStanford university schoolAlbumin improvements calledRenal medicineKarolinska institutetMedscape medical

Clazakizumab, an IL-6 Inhibitor, Could Reduce Cardiovascular Risk in Patients on Dialysis

A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.

Glenn chertowEuropean renal association congressStanford health glenn chertowStanford healthStanford medicine

Device Makes Eyes the Window to the Kidneys - San Diego Business Journal

Device Makes Eyes the Window to the Kidneys - San Diego Business Journal
sdbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sdbj.com Daily Mail and Mail on Sunday newspapers.

New zealandSan diegoUnited statesStanford universityLa jollaToku mykidneyEhsan vaghefiGlenn chertowDavid squirrellToku incUniversity of aucklandNational kidney foundationZealand diabetic screening programGenesis of toku incNational visionDrug administration

FDA approves Akebia Therapeutics Vafseo

FDA approves Akebia Therapeutics Vafseo
drugstorenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from drugstorenews.com Daily Mail and Mail on Sunday newspapers.

Glenn chertowDrug administrationStanford universitySteering committeeAkebia therapeuticsExecutive steering committee

Vertex Pharmaceuticals Incorporated: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Incorporated: Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomGlenn chertowHeather nicholsGlennm chertowMiroslava minkovaSusie lisaManisha paiCarmen bozicDennis riedlEuropean medicines agencyGlobal medicines developmentProgram steering committeeCompanies to workExchange commission